Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Neurosurgery
|
January 18, 2020
Concussion Clinical Profiles Screening (CP Screen) Tool: Preliminary Evidence to Inform a Multidisciplinary Approach
Anthony P Kontos, R J Elbin, Alicia Trbovich, et al.
Arthritis Research & Therapy
|
December 17, 2015
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand, Sima Ahadieh, Jonathan French, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 5, 2025
Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema
Ramon Garcia, Shen Cheng, Fiona Glassman, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2019
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Dan Lu, Chunze Li, Matthew Riggs, et al.
British Journal of Clinical Pharmacology
|
July 23, 2017
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens
Shang-Chiung Chen, Angelica Quartino, Daniel Polhamus, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 29, 2021
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
Ophelia Yin, Hamim Zahir, Jonathan French, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 9, 2022
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development
Kosalaram Goteti, Jonathan French, Ramon Garcia, et al.
Antimicrobial Agents and Chemotherapy
|
July 20, 2016
Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity
Brent J Yamamoto, Annette M Shadiack, Sarah Carpenter, et al.
Cancer Chemotherapy and Pharmacology
|
October 13, 2017
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Chunze Li, Bei Wang, Shang-Chiung Chen, et al.
Clinical Pharmacology and Therapeutics
|
October 19, 2022
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Katherine Kay, Justin Goodwin, Hanna Ehrlich, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Neurosurgery
|
January 18, 2020
Concussion Clinical Profiles Screening (CP Screen) Tool: Preliminary Evidence to Inform a Multidisciplinary Approach
Anthony P Kontos, R J Elbin, Alicia Trbovich, et al.
Arthritis Research & Therapy
|
December 17, 2015
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand, Sima Ahadieh, Jonathan French, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 5, 2025
Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema
Ramon Garcia, Shen Cheng, Fiona Glassman, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2019
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Dan Lu, Chunze Li, Matthew Riggs, et al.
British Journal of Clinical Pharmacology
|
July 23, 2017
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens
Shang-Chiung Chen, Angelica Quartino, Daniel Polhamus, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 29, 2021
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
Ophelia Yin, Hamim Zahir, Jonathan French, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 9, 2022
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development
Kosalaram Goteti, Jonathan French, Ramon Garcia, et al.
Antimicrobial Agents and Chemotherapy
|
July 20, 2016
Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity
Brent J Yamamoto, Annette M Shadiack, Sarah Carpenter, et al.
Cancer Chemotherapy and Pharmacology
|
October 13, 2017
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Chunze Li, Bei Wang, Shang-Chiung Chen, et al.
Clinical Pharmacology and Therapeutics
|
October 19, 2022
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Katherine Kay, Justin Goodwin, Hanna Ehrlich, et al.
Page
of 5